Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.
Researchers evaluated the prevalence of serologic immunity against hepatitis B virus in immunocompromised patients with pediatric-onset inflammatory bowel disease and rheumatologic diseases.
ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.
New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.
Recommendations are presented for testing and clinical management of health care personnel exposed to the hepatitis C virus in a US Centers for Disease Control and Prevention guidance report.
Routine hepatitis C virus testing at federally qualified health centers would be cost-effective and could improve outcomes for people with HCV infections.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Researchers found that no patients with concomitant COVID-19 and hepatitis B virus infection progressed to severe or critically ill status during hospitalization, but many had abnormal liver function tests on admission.
TDF therapy resulted in greater rates of elastographic reversion of cirrhosis in patients with chronic hepatitis B at year 5 compared with entecavir.
A combined hepatitis A and typhus vaccine in Australia for use in patients aged > 16 years was shown to be well-tolerated in children aged 2 to 16 years.
Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).
Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.
The U.S. Preventive Services Task Force recommends screening adolescents and adults at increased risk for hepatitis B virus infection.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
The persistence of hepatitis E virus (HEV) markers after acute self-limited hepatitis E was assessed and according to the data published in Journal of Viral Hepatitis, the serologic test HEV-Ag performed best overall.
In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.
New polices, including testing for hepatitis C virus (HCV) during pregnancy, may increase HCV identification in the pediatric population by addressing gaps in maternal HCV testing.
For people with substance use disorders, combining HIV and hepatitis C virus (HCV) testing and providing immediate test results may increase the number of people who are aware of their infection status.
Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.
Epclusa is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor.